Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study.
Granieri S, Cotsoglou C, Bonomi A, Salvatore L, Filippi R, Nigro O, Gelsomino F, Zurlo IV, Depetris I, Giampieri R, Berardi R, Morelli C, De Tursi M, Roberto M, Gjoni E, Germini A, de Angelis N, Memeo R, Facciorusso A, Garrone O, Ramai D, Ghidini M, Parisi A. Granieri S, et al. Among authors: garrone o. Cancers (Basel). 2022 Nov 9;14(22):5513. doi: 10.3390/cancers14225513. Cancers (Basel). 2022. PMID: 36428606 Free PMC article.
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M. Del Mastro L, et al. Among authors: garrone o. JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991. JAMA. 2011. PMID: 21771987 Clinical Trial.
Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.
Camerini A, Rondini M, Garrone O, Valsuani C, Donati S, Siclari O, Sgambato A, Tartarelli G, Vincenti M, Mattiot VP, Porta RP, Puccetti C, Puccinelli P, Amoroso D. Camerini A, et al. Among authors: garrone o. Cancer Biol Ther. 2009 Aug;8(15):1450-5. doi: 10.4161/cbt.8.15.8959. Epub 2009 Aug 8. Cancer Biol Ther. 2009. PMID: 19556864 Clinical Trial.
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M, Del Mastro L, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R. Venturini M, et al. Among authors: garrone o. Cancer Chemother Pharmacol. 1996;38(6):487-94. doi: 10.1007/s002800050516. Cancer Chemother Pharmacol. 1996. PMID: 8823488
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. Gori S, et al. Among authors: garrone o. PLoS One. 2015 Sep 25;10(9):e0139650. doi: 10.1371/journal.pone.0139650. eCollection 2015. PLoS One. 2015. PMID: 26406908 Free PMC article. No abstract available.
148 results